Logo image of BLUE

BLUEBIRD BIO INC (BLUE) Stock Fundamental Analysis

NASDAQ:BLUE - Nasdaq - US09609G1004 - Common Stock

7.88  -0.26 (-3.19%)

Fundamental Rating

1

BLUE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. BLUE may be in some trouble as it scores bad on both profitability and health. BLUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BLUE had negative earnings in the past year.
BLUE had a negative operating cash flow in the past year.
BLUE had negative earnings in each of the past 5 years.
In the past 5 years BLUE always reported negative operating cash flow.
BLUE Yearly Net Income VS EBIT VS OCF VS FCFBLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200M -400M -600M -800M

1.2 Ratios

BLUE has a Return On Assets of -64.62%. This is in the lower half of the industry: BLUE underperforms 62.83% of its industry peers.
Industry RankSector Rank
ROA -64.62%
ROE N/A
ROIC N/A
ROA(3y)-73.42%
ROA(5y)-60.14%
ROE(3y)-154.55%
ROE(5y)-114.15%
ROIC(3y)N/A
ROIC(5y)N/A
BLUE Yearly ROA, ROE, ROICBLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

BLUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLUE Yearly Profit, Operating, Gross MarginsBLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

BLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLUE has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BLUE has been reduced compared to 5 years ago.
The debt/assets ratio for BLUE is higher compared to a year ago.
BLUE Yearly Shares OutstandingBLUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
BLUE Yearly Total Debt VS Total AssetsBLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -15.85, we must say that BLUE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.85, BLUE is not doing good in the industry: 83.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -15.85
ROIC/WACCN/A
WACC10.23%
BLUE Yearly LT Debt VS Equity VS FCFBLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 0.51 indicates that BLUE may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.51, BLUE is doing worse than 93.63% of the companies in the same industry.
A Quick Ratio of 0.33 indicates that BLUE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.33, BLUE is doing worse than 94.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.51
Quick Ratio 0.33
BLUE Yearly Current Assets VS Current LiabilitesBLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BLUE have decreased strongly by -2960.86% in the last year.
BLUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 143.67%.
The Revenue for BLUE have been decreasing by -11.58% on average. This is quite bad
EPS 1Y (TTM)-2960.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.03%
Revenue 1Y (TTM)143.67%
Revenue growth 3YN/A
Revenue growth 5Y-11.58%
Sales Q2Q%-14.36%

3.2 Future

The Earnings Per Share is expected to grow by 14.13% on average over the next years. This is quite good.
BLUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.17% yearly.
EPS Next Y21.19%
EPS Next 2Y32.27%
EPS Next 3Y16.69%
EPS Next 5Y14.13%
Revenue Next Year75.14%
Revenue Next 2Y143.98%
Revenue Next 3Y97.06%
Revenue Next 5Y65.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLUE Yearly Revenue VS EstimatesBLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BLUE Yearly EPS VS EstimatesBLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLUE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLUE Price Earnings VS Forward Price EarningsBLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLUE Per share dataBLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

BLUE's earnings are expected to grow with 16.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.27%
EPS Next 3Y16.69%

More info and screens

0

5. Dividend

5.1 Amount

BLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEBIRD BIO INC

NASDAQ:BLUE (1/22/2025, 11:49:26 AM)

7.88

-0.26 (-3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners42.56%
Inst Owner Change-0.25%
Ins Owners0.38%
Ins Owner Change9.33%
Market Cap76.59M
Analysts72
Price Target38.47 (388.2%)
Short Float %N/A
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.88%
Min EPS beat(2)1.18%
Max EPS beat(2)16.57%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.64%
Min Revenue beat(2)-42.36%
Max Revenue beat(2)-34.92%
Revenue beat(4)0
Avg Revenue beat(4)-26.16%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)-6.86%
Revenue beat(8)0
Avg Revenue beat(8)-42.91%
Revenue beat(12)2
Avg Revenue beat(12)-19.38%
Revenue beat(16)2
Avg Revenue beat(16)-139.21%
PT rev (1m)1500.03%
PT rev (3m)1210.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-1814.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50.94%
Revenue NY rev (1m)-2.71%
Revenue NY rev (3m)-23.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.65
EYN/A
EPS(NY)-8.82
Fwd EYN/A
FCF(TTM)-23.77
FCFYN/A
OCF(TTM)-23.01
OCFYN/A
SpS5.47
BVpS-0.6
TBVpS-2.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.42%
ROA(5y)-60.14%
ROE(3y)-154.55%
ROE(5y)-114.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.08%
Cap/Sales 13.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.51
Quick Ratio 0.33
Altman-Z -15.85
F-Score2
WACC10.23%
ROIC/WACCN/A
Cap/Depr(3y)137.67%
Cap/Depr(5y)200.04%
Cap/Sales(3y)342.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2960.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.03%
EPS Next Y21.19%
EPS Next 2Y32.27%
EPS Next 3Y16.69%
EPS Next 5Y14.13%
Revenue 1Y (TTM)143.67%
Revenue growth 3YN/A
Revenue growth 5Y-11.58%
Sales Q2Q%-14.36%
Revenue Next Year75.14%
Revenue Next 2Y143.98%
Revenue Next 3Y97.06%
Revenue Next 5Y65.17%
EBIT growth 1Y5.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.12%
EBIT Next 3Y27.14%
EBIT Next 5Y25.4%
FCF growth 1Y48.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.74%
OCF growth 3YN/A
OCF growth 5YN/A